. Author manuscript; available in PMC: 2013 Dec 2.

Published in final edited form as: Clin Cancer Res. 2012 Jun 18;18(17):10.1158/1078-0432.CCR-11-3169. doi: 10.1158/1078-0432.CCR-11-3169

Table 6.

Adjusted hazard ratios (HR) for EBV status on survival outcomes.

All DLBCL	Overall mortality		Lymphoma specific-mortality

	HR (95% confidence interval)	p-value	HR (95% confidence interval)	p-value
Multivariable Model 1: Adjusting for IPI^a	3.3 (1.6–6.6)	<0.01	4.6 (1.8–11.4)	<0.01

Multivariable Model 2: Adjusting for propensity score^b	2.1 (1.0–4.5)	0.06	2.8 (1.1–7.7)	0.04

Centroblastic DLBCL
Multivariable Model 1: Adjusting for IPI^a	1.9 (0.9–3.8)	0.08	2.8 (1.2–6.8)	0.02

Multivariable Model 2: Adjusting for propensity score^b	2.9 (1.1–7.4)	0.03	4.3 (1.1–16.8)	0.04

Patients on standard chemotherapy

Multivariable Model 1: Adjusting for IPI^a	3.3 (1.4–7.8)	<0.01	3.3 (1.1–10.0)	0.03

Multivariable Model 2: Adjusting for propensity score^b	2.9 (1.1–7.4)	0.03	3.1 (0.9–10.0)	0.06

IPI: International Prognostic Index.

Model adjusted for propensity score. Variables used to create propensity score include: age (<=60 vs. >60 years), gender, ethnicity (Hispanic vs. non-Hispanic), DLBCL subtype (centroblastic, immunoblastic, plasmablastic), stage (III, IV, vs. others), extranodal involvement (disseminated vs.other), elevated serum lactose dehydrogenase level at DLBCL diagnosis, ECOG performance status (≥2 vs. <2), prior AIDS diagnosis (yes vs. no) and CD4 cell count at diagnosis (< 200 vs. ≥200/mm³).